Prion protein oligomer and its neurotoxicity

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 6, 2013, Pages 442-451

  Huang, Pei ^a   Lian, Fulin ^b   Wen, Yi ^b   Guo, Chenyun ^c   Lin, Donghai ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c XIAMEN UNIVERSITY   (China)

Author keywords

Neurotoxicity; Oligomer; Prion; Transmissible spongiform encephalopathies

Indexed keywords

BIOPOLYMER; OLIGOMER;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; NEUROTOXICITY; PRION; PRION DISEASE; PROTEIN CONFORMATION; PROTEIN FOLDING; REVIEW;

NEUROTOXICITY; OLIGOMER; PRION; TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES;

ANIMALS; BIOPOLYMERS; HUMANS; MODELS, MOLECULAR; PRIONS; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 84879243835     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt037     Document Type: Review

References (104)

1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998, 95: 13363-13383.
2. Aguzzi A and Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004, 116: 313-327.
3. Stohr J, Weinmann N, Wille H, Kaimann T, Nagel-Steger L, Birkmann E and Panza G, et al. Mechanisms of prion protein assembly into amyloid. Proc Natl Acad Sci USA 2008, 105: 2409-2414.
4. Aguzzi A, Sigurdson C and Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008, 3: 11-40.
5. Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR and Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 2011, 470: 540-542.
6. Soto C. Prion hypothesis: the end of the controversy? Trends Biochem Sci 2011, 36: 151-158.
7. Dobson CM. Getting out of shape. Nature 2002, 418: 729-730.
8. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003, 4: 49-60.
9. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 2006, 27: 570-575.
10. Nelson R and Eisenberg D. Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 2006, 16: 260-265.
11. Gunther EC and Strittmatter SM. Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. J Mol Med 2010, 88: 331-338.
12. Hardy J and Gwinn-Hardy K. Genetic classification of primary neurodegenerative disease. Science 1998, 282: 1075-1079.
13. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB and Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 1997, 273: 729-739.
14. Dobson CM. The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 2001, 356: 133-145.
15. Yankner BA, Duffy LK and Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250: 279-282.
16. Pike CJ, Walencewicz AJ, Glabe CG and Cotman CW. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 1991, 563: 311-314.
17. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG and Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993, 13: 1676-1687.
18. Prusiner SB. Early evidence that a protease-resistant protein is an active component of the infectious prion. Cell 2004, 116(Suppl 2): S109.
19. Wickner RB. Prions of yeast and heat-shock protein 104: 'coprion' and cure. Trends Microbiol 1995, 3: 367-369.
20. Marx J. Alzheimer's debate boils over. Science 1992, 257: 1336-1338.
21. Dickson DW and Yen SH. Beta-amyloid deposition and paired helical filament formation: which histopathological feature is more significant in Alzheimer's disease? Neurobiol Aging 1989, 10: 402-404.
22. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R and Hansen LA, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30: 572-580.
23. Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA and Finch CE. Purification and characterization of brain clusterin. Biochem Biophys Res Commun 1994, 204: 1131-1136.
24. Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE and Rozovsky I, et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 1995, 136: 22-31.
25. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF and Caughey B. The most infectious prion protein particles. Nature 2005, 437: 257-261.
26. Simoneau S, Rezaei H, Salès N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C and Fournier JG, et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog 2007, 3: e125.
27. Laganowsky A, Liu C, Sawaya MR, Whitelegge JP, Park J, Zhao M and Pensalfini A, et al. Atomic view of a toxic amyloid small oligomer. Science 2012, 335: 1228-1231.
28. Taguchi H and Kawai-Noma S. Amyloid oligomers: diffuse oligomerbased transmission of yeast prions. FEBS J 2010, 277: 1359-1368.
29. Morales R, Green KM and Soto C. Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets 2009, 8: 363-371.
30. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J and Soto C. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 2010, 30: 4528-4535.
31. Brown DR, Wong BS, Hafiz F, Clive C, Haswell SJ and Jones IM. Normal prion protein has an activity like that of superoxide dismutase. Biochem J 1999, 344: 1-5.
32. Stahl N and Prusiner SB. Prions and prion proteins. FASEB J 1991, 5: 2799-2807.
33. Calzolai L, Lysek DA, Guntert P, von Schroetter C, Riek R, Zahn R and Wüthrich K. NMR structures of three single-residue variants of the human prion protein. Proc Natl Acad Sci USA 2000, 97: 8340-8345.
34. Khurana R, Ionescu-Zanetti C, Pope M, Li J, Nielson L, Ramirez-Alvarado M and Regan L, et al. A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys J 2003, 85: 1135-1144.
35. Jimenez JL, Guijarro JI, Orlova E, Zurdo J, Dobson CM, Sunde M and Saibil HR. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J 1999, 18: 815-821.
36. Jimenez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM and Saibil HR. The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci USA 2002, 99: 9196-9201.
37. Govaerts C, Wille H, Prusiner SB and Cohen FE. Evidence for assembly of prions with left-handed beta-helices into trimers. Proc Natl Acad Sci USA 2004, 101: 8342-8347.
38. DeMarco ML and Daggett V. Molecular mechanism for low pH triggered misfolding of the human prion protein. Biochemistry 2007, 46: 3045-3054.
39. Tycko R, Savtchenko R, Ostapchenko VG, Makarava N and Baskakov IV. The alpha-helical C-terminal domain of full-length recombinant PrP converts to an in-register parallel beta-sheet structure in PrP fibrils: evidence from solid state nuclear magnetic resonance. Biochemistry 2010, 49: 9488-9497.
40. Cobb NJ, Sonnichsen FD, McHaourab H and Surewicz WK. Molecular architecture of human prion protein amyloid: a parallel, in-register betastructure. Proc Natl Acad Sci USA 2007, 104: 18946-18951.
41. Lee SW, Mou Y, Lin SY, Chou FC, Tseng WH, Chen CH and Lu CY, et al. Steric zipper of the amyloid fibrils formed by residues 109-122 of the Syrian hamster prion protein. J Mol Biol 2008, 378: 1142-1154.
42. Selvaggini C, De Gioia L, Cantu L, Ghibaudi E, Diomede L, Passerini F and Forloni G, et al. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem Biophys Res Commun 1993, 194: 1380-1386.
43. Ettaiche M, Pichot R, Vincent JP and Chabry J. In vivo cytotoxicity of the prion protein fragment 106-126. J Biol Chem 2000, 275: 36487-36490.
44. Walsh P, Simonetti K and Sharpe S. Core structure of amyloid fibrils formed by residues 106-126 of the human prion protein. Structure 2009, 17: 417-426.
45. Vorberg I, Groschup MH, Pfaff E and Priola SA. Multiple amino acid residues within the rabbit prion protein inhibit formation of its abnormal isoform. J Virol 2003, 77: 2003-2009.
46. Chianini F, Fernndez-Borges N, Vidal E, Gibbard L, Pintado B, de Castro J and Priola SA, et al. Rabbits are not resistant to prion infection. Proc Natl Acad Sci USA 2012, 109: 5080-5085.
47. Fernandez-Borges N, Chianini F, Erana H, Vidal E, Eaton SL, Pintado B and Finlayson J, et al. Naturally prion resistant mammals: A utopiä Prion 2012, 6: 425-429.
48. Wen Y, Li J, Xiong M, Peng Y, Yao W, Hong J and Lin D. Solution structure and dynamics of the I214V mutant of the rabbit prion protein. PLoS One 2010, 5: e13273.
49. Wen Y, Li J, Yao W, Xiong M, Hong J, Peng Y and Xiao G, et al. Unique structural characteristics of the rabbit prion protein. J Biol Chem 2010, 285: 31682-31693.
50. Zhang JP. Studies on the structural stability of rabbit prion probed by molecular dynamics simulations of its wild-type and mutants. J Theor Biol 2010, 264: 119-122.
51. Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C and Torchia M, et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 1990, 63: 673-686.
52. Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, Burlingame AL and Prusiner SB. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 1993, 32: 1991-2002.
53. Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL and Cohen FE, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA 1997, 94: 10069-10074.
54. Cordeiro Y, Machado F, Juliano L, Juliano MA, Brentani RR, Foguel D and Silva JL. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J Biol Chem 2001, 276: 49400-49409.
55. Deleault NR, Lucassen RW and Supattapone S. RNA molecules stimulate prion protein conversion. Nature 2003, 425: 717-720.
56. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW and Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457: 1128-1132.
57. Silva JL, Vieira TC, Gomes MP, Rangel LP, Scapin SM and Cordeiro Y. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion. Methods 2011, 53: 306-317.
58. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216: 136-144.
59. DeArmond SJ, McKinley MP, Barry RA, Braunfeld MB, McColloch JR and Prusiner SB. Identification of prion amyloid filaments in scrapie-infected brain. Cell 1985, 41: 221-235.
60. Swietnicki W, Petersen R, Gambetti P and Surewicz WK. pH-dependent stability and conformation of the recombinant human prion protein PrP(90-231). J Biol Chem 1997, 272: 27517-27520.
61. Swietnicki W, Morillas M, Chen SG, Gambetti P and Surewicz WK. Aggregation and fibrillization of the recombinant human prion protein huPrP90-231. Biochemistry 2000, 39: 424-431.
62. Apetri AC and Surewicz WK. Atypical effect of salts on the thermodynamic stability of human prion protein. J Biol Chem 2003, 278: 22187-22192.
63. Lu BY, Beck PJ and Chang JY. Oxidative folding of murine prion mPrP(23-231). Eur J Biochem 2001, 268: 3767-3773.
64. Lu BY and Chang JY. Isolation of isoforms of mouse prion protein with PrP(SC)-like structural properties. Biochemistry 2001, 40: 13390-13396.
65. Turk E, Teplow DB, Hood LE and Prusiner SB. Purification and properties of the cellular and scrapie hamster prion proteins. Eur J Biochem 1988, 176: 21-30.
66. Li J, Mei FH, Xiao GF, Guo CY and Lin DH. 1H, 13C and 15N resonance assignments of rabbit prion protein (91-228). J Biomol NMR 2007, 38: 181.
67. Baskakov IV, Legname G, Baldwin MA, Prusiner SB and Cohen FE. Pathway complexity of prion protein assembly into amyloid. J Biol Chem 2002, 277: 21140-21148.
68. Bocharova OV, Breydo L, Parfenov AS, Salnikov VV and Baskakov IV. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J Mol Biol 2005, 346: 645-659.
69. Lee S and Eisenberg D. Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process. Nat Struct Biol 2003, 10: 725-730.
70. Gerber R, Tahiri-Alaoui A, Hore PJ and James W. Oligomerization of the human prion protein proceeds via a molten globule intermediate. J Biol Chem 2007, 282: 6300-6307.
71. O'Sullivan DB, Jones CE, Abdelraheim SR, Thompsett AR, Brazier MW, Toms H and Brown DR, et al. NMR characterization of the pH 4 beta-intermediate of the prion protein: the N-terminal half of the protein remains unstructured and retains a high degree of flexibility. Biochem J 2007, 401: 533-540.
72. Rezaei H, Eghiaian F, Perez J, Doublet B, Choiset Y, Haertle T and Grosclaude J. Sequential generation of two structurally distinct ovine prion protein soluble oligomers displaying different biochemical reactivities. J Mol Biol 2005, 347: 665-679.
73. Sasaki K, Gaikwad J, Hashiguchi S, Kubota T, Sugimura K, Kremer W and Kalbitzer HR, et al. Reversible monomer-oligomer transition in human prion protein. Prion 2008, 2: 118-122.
74. Jain S and Udgaonkar JB. Defining the pathway of worm-like amyloid fibril formation by the mouse prion protein by delineation of the productive and unproductive oligomerization reactions. Biochemistry 2011, 50: 1153-1161.
75. Hesketh S, Thompsett AR and Brown DR. Prion protein polymerisation triggered by manganese-generated prion protein seeds. J Neurochem 2012, 120: 177-189.
76. Scouras AD and Daggett V. Disruption of the X-loop turn of the prion protein linked to scrapie resistance. Protein Eng Des Sel 2012, 25: 243-249.
77. Singh J, Sabareesan AT, Mathew MK and Udgaonkar JB. Development of the structural core and of conformational heterogeneity during the conversion of oligomers of the mouse prion protein to worm-like amyloid fibrils. J Mol Biol 2012, 423: 217-231.
78. Kessels HW, Nguyen LN, Nabavi S and Malinow R. The prion protein as a receptor for amyloid-beta. Nature 2010, 466: E3-E4.
79. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J and Mansuy IM, et al. Prion protein and Ab-related synaptic toxicity impairment. EMBO Mol Med 2010, 2: 306-314.
80. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E and Tapella L, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 2010, 107: 2295-2300.
81. Benilova I and De Strooper B. Prion protein in Alzheimer's pathogenesis: a hot and controversial issue. EMBO Mol Med 2010, 2: 289-290.
82. Lindgren M and Hammarstrom P. Amyloid oligomers: spectroscopic characterization of amyloidogenic protein states. FEBS J 2010, 277: 1380-1388.
83. Malchiodi-Albedi F, Paradisi S, Matteucci A, Frank C and Diociaiuti M. Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. Int J Alzheimer's Dis 2011, 2011: 906964.
84. Morillas M, Vanik DL and Surewicz WK. On the mechanism of alphahelix to beta-sheet transition in the recombinant prion protein. Biochemistry 2001, 40: 6982-6987.
85. Apetri AC and Surewicz WK. Kinetic intermediate in the folding of human prion protein. J Biol Chem 2002, 277: 44589-44592.
86. Semisotnov GV, Rodionova NA, Razgulyaev OI, Uversky VN, Gripas AF and Gilmanshin RI. Study of the 'molten globulé intermediate state in protein folding by a hydrophobic fluorescent probe. Biopolymers 1991, 31: 119-128.
87. Hornemann S and Glockshuber R. A scrapie-like unfolding intermediate of the prion protein domain PrP(121-231) induced by acidic pH. Proc Natl Acad Sci USA 1998, 95: 6010-6014.
88. Wong KP and Tanford C. Denaturation of bovine carbonic anhydrase B by guanidine hydrochloride. A process involving separable sequential conformational transitions. J Biol Chem 1973, 248: 8518-8523.
89. Kuwajima K. A folding model of alpha-lactalbumin deduced from the three-state denaturation mechanism. J Mol Biol 1977, 114: 241-258.
90. Carrey EA and Pain RH. Conformation of a stable intermediate on the folding pathway of Staphylococcus aureus penicillinase. Biochim Biophys Acta 1978, 533: 12-22.
91. Nozaka M, Kuwajima K, Nitta K and Sugai S. Detection and characterization of the intermediate on the folding pathway of human alphalactalbumin. Biochemistry 1978, 17: 3753-3758.
92. Kim PS and Baldwin RL. Specific intermediates in the folding reactions of small proteins and the mechanism of protein folding. Annu Rev Biochem 1982, 51: 459-489.
93. Dolgikh DA, Abaturov LV, Brazhnikov, Lebedev IuO and Chirgadze IuN. Acid form of carbonic anhydrase: 'molten globulé with a secondary structure. Dokl Akad Nauk SSSR 1983, 272: 1481-1484.
94. Dolgikh DA, Abaturov LV, Bolotina IA, Brazhnikov EV, Bychkova VE, Gilmanshin RI and Lebedev YuO, et al. Compact state of a protein molecule with pronounced small-scale mobility: bovine alpha-lactalbumin. Eur Biophys J 1985, 13: 109-121.
95. Gilmanshin RI and Ptitsyn OB. An early intermediate of refolding alphalactalbumin forms within 20 ms. FEBS Lett 1987, 223: 327-329.
96. Redfield C. NMR studies of partially folded molten-globule states. Methods Mol Biol 2004, 278: 233-254.
97. Redfield C. Using nuclear magnetic resonance spectroscopy to study molten globule states of proteins. Methods 2004, 34: 121-132.
98. Rezaei H, Choiset Y, Eghiaian F, Treguer E, Mentre P, Debey P and Grosclaude J, et al. Amyloidogenic unfolding intermediates differentiate sheep prion protein variants. J Mol Biol 2002, 322: 799-7814.
99. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE and Glabe CG. Permeabilization of lipid bilayers is a common conformationdependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004, 279: 46363-46366.
100. Caughey B and Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003, 26: 267-298.
101. Race RE and Raymond GJ. Inactivation of transmissible spongiform encephalopathy (prion) agents by environ LpH. J Virol 2004, 78: 2164-2165.
102. Ksiazek J, Gaworska-Krzeminska A, Walenska G and Skokowski J. The problem of pain evaluation in the process of nursing care in thoracosurgical patients and in general surgery. Rocz Akad Med Bialymst 2005, 50(Suppl 1): 199-202.
103. Kudo W, Lee HP, Zou WQ, Wang X, Perry G, Zhu X and Smith MA, et al. Cellular prion protein is essential for oligomeric amyloidbeta- induced neuronal cell death. Hum Mol Genet 2012, 21: 1138-1144.
104. Surewicz WK and Apostol MI. Prion protein and its conformational conversion: a structural perspective. Top Curr Chem 2011, 305: 135-167.